Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc told investors that the first quarter of 2022 delivered significant opportunities for KGK Science Inc as its subsidiary signed new contracts, completed clinical research reports, obtained regulatory approvals and received other honours.
In a commercial and corporate update on the achievements of the contract research organization (CRO), Wellbeing noted that KGK’s research team finalized two clinical study reports – a coronavirus (COVID-19) virtual study and an immune function study.
KGK’s regulatory team was able to complete gap analysis for a propriety delivery system in March and obtained regulatory approvals for two clinical trials that include a mood and an immune health clinical trial. Additionally, it said the CRO’s regulatory team also conducted claims reviews for two dietary supplement companies and one food company, as well as a label review for a dietary supplement.
READ: Wellbeing Digital Sciences announces start of a global and comprehensive strategy
“The team at KGK has been busy to start 2022 and I would like to commend them on their successes this year to date. I am grateful for all the hard work that has been expended by my colleagues and staff in order to have the privilege of providing this strong update,” said Najla Guthrie, CEO of Wellbeing.
Wellbeing said KGK’s chief scientific officer, Dr Mal Evans, will be serving as a judge for the 2022 Nutraingredients Awards on May 4, 2022, which will be her second year as a judge for these prestigious awards. The awards honour the best and brightest ingredients, products, companies, people and initiatives in the nutrition and dietary supplements industry.
KGK’s director of regulatory affairs and psychedelic advisor, Andrew Charrette, has been invited to be a panellist at Lift&Co Expo in Toronto, Canada from May 12-15, 2022, where he will guide a session on New Psychedelics Data: The Latest Industry Analysis for Canadian Psychedelics.
KGK has also been invited to present virtually at Nutrition 2022 Live Online, the American Society for Nutrition’s annual flagship meeting, on June 14-16, 2022. Nutrition 2022 is an event that addresses scientific and clinical topics while offering scientific presentations, live Q&A, small group discussions and networking opportunities. Wellbeing said the meeting will allow KGK the opportunity to showcase its successful findings of a clinical trial that examined the use of natural health products to support immunity during flu season.
Regarding new business, Wellbeing said KGK signed six contracts over the last month including an Ames study, three claims reviews, and two path-to-market and gap analysis engagements. It also submitted two product licence applications, a consulting project for claims regarding a supplement and a manuscript.
“KGK, as a core component of Wellbeing and its comprehensive strategy to re-conceptualize mental health care service offerings to patients, continues to strengthen as a business,” Guthrie concluded. “We are confident in our plan to foster innovation in mental health services through contract research support, innovative solutions and digital therapeutics backed by scientific evidence, for Wellbeing’s expanding North American footprint and clinical expert network.”
Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario that provides clinical research trials on nutraceutical and emerging healthcare products.
Wellbeing, formerly KetamineOne, is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research.
Contact the author at stephen.gunnion@proactiveinvestors.com